Previous Article | Next Article 
Journal of Virology, September 2006, p. 8745-8762, Vol. 80, No. 17
0022-538X/06/$08.00+0 doi:10.1128/JVI.00956-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV-1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection
Nina R. Derby,1,2
Zane Kraft,1
Elaine Kan,3
Emma T. Crooks,4
Susan W. Barnett,3
Indresh K. Srivastava,3
James M. Binley,4 and
Leonidas Stamatatos1,2*
Seattle Biomedical Research Institute, Seattle, Washington 98109,1
Department of Pathobiology, University of Washington, Seattle, Washington 98109,2
Vaccines Research, Chiron Corporation, Emeryville, California 94608,3
Torrey Pines Institute for Molecular Studies, San Diego, California 921214
Received 10 May 2006/
Accepted 20 June 2006
The antibody responses elicited in rhesus macaques immunized with soluble human immunodeficiency virus (HIV) Env gp140 proteins derived from the R5-tropic HIV-1 SF162 virus were analyzed and compared to the broadly reactive neutralizing antibody responses elicited during chronic infection of a macaque with a simian/human immunodeficiency virus (SHIV) expressing the HIV-1 SF162 Env, SHIVSF162P4, and humans infected with heterologous HIV-1 isolates. Four gp140 immunogens were evaluated: SF162gp140,
V2gp140 (lacking the crown of the V2 loop),
V3gp140 (lacking the crown of the V3 loop), and
V2
V3gp140 (lacking both the V2 and V3 loop crowns). SF162gp140 and
V2gp140 have been previously evaluated by our group in a pilot study, but here, a more comprehensive analysis of their immunogenic properties was performed. All four gp140 immunogens elicited stronger anti-gp120 than anti-gp41 antibodies and potent homologous neutralizing antibodies (NAbs) that primarily targeted the first hypervariable region (V1 loop) of gp120, although SF162gp140 also elicited anti-V3 NAbs. Heterologous NAbs were elicited by SF162gp140 and
V2gp140 but were weak in potency and narrow in specificity. No heterologous NAbs were elicited by
V3gp140 or
V2
V3gp140. In contrast, the SHIVSF162P4-infected macaque and HIV-infected humans generated similar titers of anti-gp120 and anti-gp41 antibodies and NAbs of significant breadth against primary HIV-1 isolates, which did not target the V1 loop. The difference in V1 loop immunogenicity between soluble gp140 and virion-associated gp160 Env proteins derived from SF162 may be the basis for the observed difference in the breadth of neutralization in sera from the immunized and infected animals studied here.
* Corresponding author. Mailing address: Seattle Biomedical Research Institute, 307 Westlake Avenue North, Seattle, WA 98109. Phone: (206) 256-7200. Fax: (206) 256-7229. E-mail:
leo.stamatatos{at}sbri.org.
Supplemental material for this article may be found at http://jvi.asm.org/.
Journal of Virology, September 2006, p. 8745-8762, Vol. 80, No. 17
0022-538X/06/$08.00+0 doi:10.1128/JVI.00956-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Blish, C. A., Sather, D. N., Sellhorn, G., Stamatatos, L., Sun, Y., Srivastava, I., Barnett, S. W., Cleveland, B., Overbaugh, J., Hu, S.-l.
(2010). Comparative Immunogenicity of Subtype A Human Immunodeficiency Virus Type 1 Envelope Exhibiting Differential Exposure of Conserved Neutralization Epitopes. J. Virol.
84: 2573-2584
[Abstract]
[Full Text]
-
Xu, H., Song, L., Kim, M., Holmes, M. A., Kraft, Z., Sellhorn, G., Reinherz, E. L., Stamatatos, L., Strong, R. K.
(2010). Interactions between Lipids and Human Anti-HIV Antibody 4E10 Can Be Reduced without Ablating Neutralizing Activity. J. Virol.
84: 1076-1088
[Abstract]
[Full Text]
-
Sather, D. N., Armann, J., Ching, L. K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S., Kalams, S., Stamatatos, L.
(2009). Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection. J. Virol.
83: 757-769
[Abstract]
[Full Text]
-
Morner, A., Douagi, I., Forsell, M. N. E., Sundling, C., Dosenovic, P., O'Dell, S., Dey, B., Kwong, P. D., Voss, G., Thorstensson, R., Mascola, J. R., Wyatt, R. T., Karlsson Hedestam, G. B.
(2009). Human Immunodeficiency Virus Type 1 Env Trimer Immunization of Macaques and Impact of Priming with Viral Vector or Stabilized Core Protein. J. Virol.
83: 540-551
[Abstract]
[Full Text]
-
Bontjer, I., Land, A., Eggink, D., Verkade, E., Tuin, K., Baldwin, C., Pollakis, G., Paxton, W. A., Braakman, I., Berkhout, B., Sanders, R. W.
(2009). Optimization of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins with V1/V2 Deleted, Using Virus Evolution. J. Virol.
83: 368-383
[Abstract]
[Full Text]
-
Sundling, C., Schon, K., Morner, A., Forsell, M. N. E., Wyatt, R. T., Thorstensson, R., Hedestam, G. B. K., Lycke, N. Y.
(2008). CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J. Gen. Virol.
89: 2954-2964
[Abstract]
[Full Text]
-
Binley, J. M., Lybarger, E. A., Crooks, E. T., Seaman, M. S., Gray, E., Davis, K. L., Decker, J. M., Wycuff, D., Harris, L., Hawkins, N., Wood, B., Nathe, C., Richman, D., Tomaras, G. D., Bibollet-Ruche, F., Robinson, J. E., Morris, L., Shaw, G. M., Montefiori, D. C., Mascola, J. R.
(2008). Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C. J. Virol.
82: 11651-11668
[Abstract]
[Full Text]
-
Laird, M. E., Igarashi, T., Martin, M. A., Desrosiers, R. C.
(2008). Importance of the V1/V2 Loop Region of Simian-Human Immunodeficiency Virus Envelope Glycoprotein gp120 in Determining the Strain Specificity of the Neutralizing Antibody Response. J. Virol.
82: 11054-11065
[Abstract]
[Full Text]
-
Vaine, M., Wang, S., Crooks, E. T., Jiang, P., Montefiori, D. C., Binley, J., Lu, S.
(2008). Improved Induction of Antibodies against Key Neutralizing Epitopes by Human Immunodeficiency Virus Type 1 gp120 DNA Prime-Protein Boost Vaccination Compared to gp120 Protein-Only Vaccination. J. Virol.
82: 7369-7378
[Abstract]
[Full Text]
-
Kraft, Z., Strouss, K., Sutton, W. F., Cleveland, B., Tso, F. Y., Polacino, P., Overbaugh, J., Hu, S.-L., Stamatatos, L.
(2008). Characterization of Neutralizing Antibody Responses Elicited by Clade A Envelope Immunogens Derived from Early Transmitted Viruses. J. Virol.
82: 5912-5921
[Abstract]
[Full Text]
-
Ching, L. K., Vlachogiannis, G., Bosch, K. A., Stamatatos, L.
(2008). The First Hypervariable Region of the gp120 Env Glycoprotein Defines the Neutralizing Susceptibility of Heterologous Human Immunodeficiency Virus Type 1 Isolates to Neutralizing Antibodies Elicited by the SF162gp140 Immunogen. J. Virol.
82: 949-956
[Abstract]
[Full Text]
-
DeVico, A., Fouts, T., Lewis, G. K., Gallo, R. C., Godfrey, K., Charurat, M., Harris, I., Galmin, L., Pal, R.
(2007). Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc. Natl. Acad. Sci. USA
104: 17477-17482
[Abstract]
[Full Text]
-
Kraft, Z., Derby, N. R., McCaffrey, R. A., Niec, R., Blay, W. M., Haigwood, N. L., Moysi, E., Saunders, C. J., Wrin, T., Petropoulos, C. J., McElrath, M. J., Stamatatos, L.
(2007). Macaques Infected with a CCR5-Tropic Simian/Human Immunodeficiency Virus (SHIV) Develop Broadly Reactive Anti-HIV Neutralizing Antibodies. J. Virol.
81: 6402-6411
[Abstract]
[Full Text]
-
Law, M., Cardoso, R. M. F., Wilson, I. A., Burton, D. R.
(2007). Antigenic and Immunogenic Study of Membrane-Proximal External Region-Grafted gp120 Antigens by a DNA Prime-Protein Boost Immunization Strategy. J. Virol.
81: 4272-4285
[Abstract]
[Full Text]
-
Honnen, W. J., Krachmarov, C., Kayman, S. C., Gorny, M. K., Zolla-Pazner, S., Pinter, A.
(2007). Type-Specific Epitopes Targeted by Monoclonal Antibodies with Exceptionally Potent Neutralizing Activities for Selected Strains of Human Immunodeficiency Virus Type 1 Map to a Common Region of the V2 Domain of gp120 and Differ Only at Single Positions from the Clade B Consensus Sequence. J. Virol.
81: 1424-1432
[Abstract]
[Full Text]